Jazz Pharmaceuticals’ (JAZZ) “Buy” Rating Reaffirmed at Needham & Company LLC

Jazz Pharmaceuticals (NASDAQ:JAZZ)‘s stock had its “buy” rating reissued by investment analysts at Needham & Company LLC in a note issued to investors on Thursday, Benzinga reports. They currently have a $207.00 target price on the specialty pharmaceutical company’s stock. Needham & Company LLC’s price target would indicate a potential upside of 85.57% from the company’s current price.

Other equities analysts have also recently issued reports about the stock. JPMorgan Chase & Co. boosted their price target on shares of Jazz Pharmaceuticals from $190.00 to $202.00 and gave the company an “overweight” rating in a report on Monday, August 19th. Morgan Stanley dropped their target price on Jazz Pharmaceuticals from $160.00 to $150.00 and set an “equal weight” rating on the stock in a research report on Friday, July 12th. StockNews.com upgraded Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 1st. Royal Bank of Canada increased their price objective on Jazz Pharmaceuticals from $175.00 to $179.00 and gave the stock an “outperform” rating in a report on Wednesday, October 23rd. Finally, Wells Fargo & Company reduced their target price on shares of Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating for the company in a research note on Thursday, August 1st. Three analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $173.57.

Jazz Pharmaceuticals Trading Up 0.1 %

NASDAQ JAZZ opened at $111.55 on Thursday. The firm’s 50 day moving average price is $110.42 and its two-hundred day moving average price is $109.61. The stock has a market cap of $6.89 billion, a price-to-earnings ratio of 19.17, a PEG ratio of 1.37 and a beta of 0.57. Jazz Pharmaceuticals has a twelve month low of $99.06 and a twelve month high of $134.48. The company has a debt-to-equity ratio of 1.36, a quick ratio of 2.02 and a current ratio of 2.37.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Wednesday, November 6th. The specialty pharmaceutical company reported $5.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.54 by $1.32. Jazz Pharmaceuticals had a net margin of 10.10% and a return on equity of 28.65%. The business had revenue of $1.05 billion during the quarter, compared to analyst estimates of $1.04 billion. Equities analysts anticipate that Jazz Pharmaceuticals will post 16.02 EPS for the current year.

Insider Activity

In related news, CEO Bruce C. Cozadd sold 1,000 shares of the business’s stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $110.84, for a total transaction of $110,840.00. Following the completion of the transaction, the chief executive officer now owns 428,976 shares of the company’s stock, valued at approximately $47,547,699.84. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CEO Bruce C. Cozadd sold 1,000 shares of the company’s stock in a transaction on Friday, November 1st. The shares were sold at an average price of $110.84, for a total transaction of $110,840.00. Following the completion of the transaction, the chief executive officer now directly owns 428,976 shares in the company, valued at $47,547,699.84. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Mary Elizabeth Henderson sold 1,410 shares of the stock in a transaction on Friday, September 6th. The shares were sold at an average price of $108.30, for a total transaction of $152,703.00. Following the completion of the sale, the senior vice president now directly owns 14,531 shares of the company’s stock, valued at approximately $1,573,707.30. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Natixis Advisors LLC lifted its position in shares of Jazz Pharmaceuticals by 7.6% in the 3rd quarter. Natixis Advisors LLC now owns 22,834 shares of the specialty pharmaceutical company’s stock worth $2,544,000 after acquiring an additional 1,603 shares during the period. CIBC Asset Management Inc acquired a new position in shares of Jazz Pharmaceuticals in the third quarter valued at $209,000. Kovack Advisors Inc. lifted its position in Jazz Pharmaceuticals by 20.4% in the third quarter. Kovack Advisors Inc. now owns 57,672 shares of the specialty pharmaceutical company’s stock worth $6,425,000 after purchasing an additional 9,783 shares during the period. MQS Management LLC acquired a new stake in Jazz Pharmaceuticals during the third quarter worth $253,000. Finally, Victory Capital Management Inc. increased its holdings in Jazz Pharmaceuticals by 23.3% in the 3rd quarter. Victory Capital Management Inc. now owns 253,299 shares of the specialty pharmaceutical company’s stock valued at $28,220,000 after buying an additional 47,807 shares during the period. 89.14% of the stock is currently owned by institutional investors.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.